NCT00237237

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 588 (planned)
• Sponsor: Novartis · Industry
• Sex: All
• Age: 18 Years – 77 Years
• Healthy volunteers: —

Summary

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long-term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	vildagliptin

Timeline

• Start date: 2005-10-01
• Primary completion: 2007-02-01
• First posted: 2005-10-12
• Last updated: 2017-02-07

Locations

2 sites across 2 countries: United States, Germany